14 completed. 14 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 14 |
| Phase 2 | 4 | Completed 4 |
Follow Heroin Dependence: new trials by email Literature Review of Heroin Dependence trials Research Report on Heroin Dependence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) Hydromorphone, Injectable, Diacetylmorphine, injectable, Hydromorphone, liquid oral - Opioid Dependence, Heroin Dependence | Phase 3 | Completed | University of British Columbia | 202 | 2011-12-01 | 2016-06-07 |
| Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone Intranasal challenge drug - Heroin Dependence | Phase 3 | Completed | New York State Psychiatric Institute | 27 | 2009-05-01 | 2017-09-08 |
| Buprenorphine for Prisoners Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP - Heroin Addiction | Phase 3 | Completed | Friends Research Institute, Inc. | 213 | 2008-09-01 | 2018-08-29 |
| ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence VIVITROL® 380 mg, Placebo - Opiate Dependence | Phase 3 | Completed | Alkermes, Inc. | 250 | 2008-06-01 | 2017-02-10 |
| Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Vivitrol, memantine - Opioid Dependence, Heroin Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 82 | 2008-06-01 | 2018-07-17 |
| Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial Buprenorphine - Opioid-Related Disorders, Heroin Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 20 | 2007-12-01 | 2019-04-24 |
| Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone depot naltrexone, Oral Naltrexone - Opiate Dependence, Heroin Dependence | Phase 3 | Completed | New York State Psychiatric Institute | 60 | 2007-09-01 | 2017-08-25 |
| Addiction Treatment in Russia: Oral vs. Naltrexone Implant naltrexone implant, oral naltrexone, oral placebo naltrexone - Heroin Dependence, Opioid-Related Disorders | Phase 2 / Phase 3 | Completed | University of Pennsylvania | 306 | 2006-07-01 | 2019-03-18 |
| Directly Administered HIV Therapy in Methadone Clinics Directly administered antiretroviral therapy (DAART) - HIV Infections, Heroin Dependence | Phase 2 / Phase 3 | Completed | Johns Hopkins University | 107 | 2006-04-01 | 2015-04-15 |
| Methadone Maintenance for Prisoners Counseling Only, Counseling + Transfer, Counseling + Methadone - Heroin Addiction | Phase 3 | Completed | Friends Research Institute, Inc. | 211 | 2003-09-01 | 2014-04-03 |
| Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 Buprenorphine/naloxone - Heroin Dependence, Morphine Dependence | Phase 3 | Completed | University of California, Los Angeles | 163 | 2001-02-01 | 2017-01-12 |
| Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Buprenorphine/naloxone - Heroin Dependence, Morphine Dependence | Phase 3 | Completed | University of California, Los Angeles | 341 | 2001-01-01 | 2017-01-12 |
| Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1 Buprenorphine/naloxone - Heroin Dependence, Substance-Related Disorders | Phase 3 | Completed | National Institute on Drug Abuse (NIDA) | 1996-04-01 | 2017-01-16 | |
| Study Comparing Liquid and Tablet Buprenorphine Formulations - 5 Buprenorphine - Heroin Dependence | Phase 3 | Completed | National Institute on Drug Abuse (NIDA) | 2005-11-07 |
Opioid-Related Disorders (10) · Morphine Dependence (2) · Substance Withdrawal Syndrome (2) · Behavior, Addictive (1) · HIV Infections (1) · Substance-Related Disorders (1)
Chemically-Induced Disorders (14) · Mental Disorders (14) · Narcotic-Related Disorders (14) · Substance-Related Disorders (13) · Opioid-Related Disorders (4) · Behavior (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Compulsive Behavior (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Impulsive Behavior (1) · Infections (1) · Lentivirus Infections (1)
Buprenorphine, Naloxone Drug Combination (4) · Naltrexone (3) · vivitrol (3) · Buprenorphine (2) · Counseling (1) · Fluid Therapy (1) · Heroin (1) · Hydromorphone (1) · Injections (1) · Memantine (1) · Methadone (1) · Parturition (1)
New York State Psychiatric Institute (4) · Friends Research Institute, Inc. (2) · National Institute on Drug Abuse (NIDA) (2) · University of California, Los Angeles (2) · Alkermes, Inc. (1) · Johns Hopkins University (1) · University of British Columbia (1) · University of Pennsylvania (1)
United States (12) · Russia (2) · Canada (1)
Walter Ling, M.D. (3) · Adam Bisaga, MD (1) · Alexander Okhapkin, Prof. (1) · Alexander Sofronov, Prof. (1) · Alexey Egorov, Prof. (1) · Andrey Anipchenko, Dr. (1) · Edvin Zvartau, Prof. (1) · Edward Nunes, M.D. (1) · Erik W Gunderson, M.D. (1) · Eugenia Oveido-Joekes, Ph.D. (1) · Evgeny Krupitsky, Prof. (1) · George Woody, MD (1) · Gregory M. Lucas, MD, PhD (1) · John Rotrosen, M.D. (1) · Maria Sullivan, M.D. (1)
PMID 40342086, PMID 17628351, PMID 18612373, PMID 18855822, PMID 19339140, PMID 21529928, PMID 21715107, PMID 22882399, PMID 22945623, PMID 23036218, PMID 23701526, PMID 23874575, PMID 25580067, PMID 25619263, PMID 25901451, PMID 27049826, PMID 27436632, PMID 28526048, PMID 31787108
K23DA020000 (1), R01DA010746 (1), R01DA015822 (1), R01DA016237 (1), R01DA017317 (1), R01DA021579 (1)